The FDA has required Johnson & Johnson to include in the package inserts of its diabetes drugs Invokamet, Invokamet XR and Invokana a boxed warning regarding the risk of leg and foot amputations from taking the active ingredient canagliflozin. A safety analysis of a study conducted last year showed an increased risk of lower-limb amputation, mainly of the forefoot and toe, in patients with a high risk of cardiovascular events.
FDA requires J&J to include boxed warning on diabetes drugs
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.